Efficacy and safety of ODM-104 compared to a standard combination (Stalevo); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson's disease and end-of-dose wearing-off
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2017
At a glance
- Drugs ODM 104 (Primary) ; Carbidopa; Levodopa; Levodopa/carbidopa/entacapone
- Indications Parkinson's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms COMPOC
- Sponsors Orion
- 13 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
- 13 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.
- 30 Jun 2017 Last checked against European Clinical Trials Database record.